Ahmed Giwa, DO
Hospitalist · Cincinnati, OHNPI 1528406840
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,862 of the $2,375 with a category attached, or 78.4%. It is spread thinly across 18 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $677, 5.6 times the $120 reported in 2019. Among hospitalist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$432
- AstraZeneca$319
- Amgen$265
- Novartis$234
- Fresenius USA Marketing, Inc.$214
- Akebia Therapeutics Inc$189
- plus $723 from 12 others
What the payments were for
- Food & beverage$1,86278%
- Education$51322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $432 |
| AstraZeneca(2 entities) | 11 | $319 |
| Amgen(2 entities) | 10 | $265 |
| Novartis | 11 | $234 |
| Fresenius USA Marketing, Inc. | 11 | $214 |
| Akebia Therapeutics Inc | 4 | $189 |
| Vifor Pharma, Inc. | 3 | $182 |
| Bayer | 4 | $165 |
| OPKO Pharmaceuticals, LLC | 6 | $109 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Travere Therapeutics, Inc. | 4 | $42 |
| Ardelyx, Inc. | 2 | $41 |
| Calliditas Therapeutics US Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$125
How this compares
$2,375 in reported general payments places this provider in the 95th percentile of 813 hospitalist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolvaptan | 13 | $44,609 |
| FarxigaDapagliflozin Propanediol | 47 | $34,125 |
| VelphoroSucroferric Oxyhydroxide | 22 | $26,097 |
| KerendiaFinerenone | 13 | $8,933 |
| Bumetanide | 40 | $2,265 |
| Calcium Acetate | 35 | $1,929 |
| Midodrine Hcl | 17 | $1,529 |
| Sevelamer Carbonate | 12 | $1,091 |
| Calcitriol | 27 | $640 |
| Furosemide | 46 | $364 |
| Spironolactone | 37 | $279 |
| Allopurinol | 54 | $198 |
| Potassium Chloride | 17 | $180 |
| Metolazone | 11 | $148 |
| Carvedilol | 12 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $319 | $34,12547 claims |
| Fresenius USA Marketing, Inc.Velphoro | $214 | $26,09722 claims |
| BayerKerendia | $165 | $8,93313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 813 hospitalist providers in Ohio.
Other hospitalist in Cincinnati
- Geeta SrivastavaCincinnati$10K
- Robert RubinCincinnati$9K
- Arunab MehtaCincinnati$4K
- Khaled Abou El-EzzCincinnati$3K
- Sajid FarooqCincinnati$3K
- Sneha CentalaCincinnati$3K
- Galina KraytermanCincinnati$3K
- Zachary SmithCincinnati$2K
- Rafael FleitesCincinnati$1K
- Marco CallirgosCincinnati$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.